Here are four takeaways:
1. The trial is being conducted under a special protocol assessment with the FDA.
2. The trial is designed to evaluate the safety and efficacy of NeoCart as a first-line therapy for full thickness knee cartilage defects in adults.
3. NeoCart is a cartilage-like, tissue engineered implant created from a patient’s own cartilage cells.
4. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
K2M Group Holdings shares hit 52-week low: 5 notes
Medovex obtains reimbursement for its DenerveX Facet Joint Syndrome Treatment: 4 takeaways
Global non-fusion spinal device market to grow – 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
